Affinity Asset Advisors LLC Cuts Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Affinity Asset Advisors LLC cut its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTAFree Report) by 21.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 795,729 shares of the company’s stock after selling 222,362 shares during the quarter. Centessa Pharmaceuticals makes up approximately 1.2% of Affinity Asset Advisors LLC’s portfolio, making the stock its 23rd largest holding. Affinity Asset Advisors LLC owned 0.82% of Centessa Pharmaceuticals worth $6,334,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its holdings in Centessa Pharmaceuticals by 371.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,394 shares of the company’s stock valued at $51,000 after purchasing an additional 5,037 shares during the last quarter. Jump Financial LLC purchased a new stake in Centessa Pharmaceuticals during the fourth quarter valued at about $114,000. Trexquant Investment LP purchased a new stake in Centessa Pharmaceuticals during the fourth quarter valued at about $114,000. Rathbones Group PLC purchased a new stake in Centessa Pharmaceuticals during the third quarter valued at about $203,000. Finally, Acuta Capital Partners LLC purchased a new stake in Centessa Pharmaceuticals during the third quarter valued at about $2,092,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Price Performance

Shares of CNTA traded up $0.04 during midday trading on Wednesday, hitting $8.48. 8,614 shares of the company traded hands, compared to its average volume of 319,032. The stock has a 50-day moving average of $9.68 and a 200-day moving average of $8.98. Centessa Pharmaceuticals plc has a one year low of $4.49 and a one year high of $12.45. The firm has a market cap of $852.09 million, a P/E ratio of -5.94 and a beta of 1.39. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.37 and a quick ratio of 10.37.

Centessa Pharmaceuticals (NASDAQ:CNTAGet Free Report) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.03. As a group, sell-side analysts predict that Centessa Pharmaceuticals plc will post -1.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, BMO Capital Markets reaffirmed an “outperform” rating and set a $15.00 price objective on shares of Centessa Pharmaceuticals in a report on Monday, April 1st. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $10.00.

View Our Latest Research Report on CNTA

Insider Buying and Selling

In related news, insider Karen M. Anderson sold 51,160 shares of the company’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $11.88, for a total value of $607,780.80. Following the transaction, the insider now directly owns 71,525 shares in the company, valued at $849,717. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 11.59% of the stock is owned by company insiders.

Centessa Pharmaceuticals Company Profile

(Free Report)

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.

Featured Stories

Want to see what other hedge funds are holding CNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centessa Pharmaceuticals plc (NASDAQ:CNTAFree Report).

Institutional Ownership by Quarter for Centessa Pharmaceuticals (NASDAQ:CNTA)

Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.